Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of , , and mutations; increased frequency...
Gespeichert in:
Veröffentlicht in: | JCI insight 2016-03, Vol.1 (3), p.e85902-e85902 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e85902 |
---|---|
container_issue | 3 |
container_start_page | e85902 |
container_title | JCI insight |
container_volume | 1 |
creator | Kardos, Jordan Chai, Shengjie Mose, Lisle E Selitsky, Sara R Krishnan, Bhavani Saito, Ryoichi Iglesia, Michael D Milowsky, Matthew I Parker, Joel S Kim, William Y Vincent, Benjamin G |
description | We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of
,
, and
mutations; increased frequency of
amplification; decreased rates of
,
, and
mutations; and decreased frequency of
amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low
activity, allowing unopposed
activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response. |
doi_str_mv | 10.1172/jci.insight.85902 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5033914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835357905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</originalsourceid><addsrcrecordid>eNpVUclOwzAQtRCIVoUP4IJy5JJix7EdX5BQxSZVggOcLSceg5GzYCdF_XsCXVQOozfSvHmzPIQuCJ4TIrLrz8rNXRPd-0c_L5jE2RGaZlTIlApcHB_kE3Qe4yfGmIg8w6w4RZNMcCkzxqfoZeH1YFyT-vY7Kb02BkLSD3UbYqIDJK6uh2aExjrfB92DSXQzRtW7Ffj1rh6HrgsQI5gzdGK1j3C-xRl6u797XTymy-eHp8XtMq1yLvu0tDRnwCyWhQEJJCecSIYLzom1UGLKy3K8iUujMZQ8M4AFtVpkAqStANMZutnodkNZg6mgGdfzqguu1mGtWu3U_0rjPtR7u1IMUypJPgpcbQVC-zVA7FXtYgXe6wbaISpSUEaZkJiNVLKhVqGNMYDdjyFY_ZqhRjPU1gz1Z8bYc3m4375j93r6A-s-iu0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835357905</pqid></control><display><type>article</type><title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kardos, Jordan ; Chai, Shengjie ; Mose, Lisle E ; Selitsky, Sara R ; Krishnan, Bhavani ; Saito, Ryoichi ; Iglesia, Michael D ; Milowsky, Matthew I ; Parker, Joel S ; Kim, William Y ; Vincent, Benjamin G</creator><creatorcontrib>Kardos, Jordan ; Chai, Shengjie ; Mose, Lisle E ; Selitsky, Sara R ; Krishnan, Bhavani ; Saito, Ryoichi ; Iglesia, Michael D ; Milowsky, Matthew I ; Parker, Joel S ; Kim, William Y ; Vincent, Benjamin G</creatorcontrib><description>We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of
,
, and
mutations; increased frequency of
amplification; decreased rates of
,
, and
mutations; and decreased frequency of
amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low
activity, allowing unopposed
activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response.</description><identifier>ISSN: 2379-3708</identifier><identifier>EISSN: 2379-3708</identifier><identifier>DOI: 10.1172/jci.insight.85902</identifier><identifier>PMID: 27699256</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Antigens, Neoplasm - metabolism ; Chemokines - immunology ; Claudins - genetics ; Cytokines - immunology ; Humans ; Immune Tolerance ; Leukocytes - immunology ; NF-kappa B - metabolism ; PPAR gamma - metabolism ; Tumor Microenvironment ; Urinary Bladder Neoplasms - classification ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - immunology</subject><ispartof>JCI insight, 2016-03, Vol.1 (3), p.e85902-e85902</ispartof><rights>Copyright © 2016, American Society for Clinical Investigation 2016 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</citedby><cites>FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033914/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033914/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27699256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kardos, Jordan</creatorcontrib><creatorcontrib>Chai, Shengjie</creatorcontrib><creatorcontrib>Mose, Lisle E</creatorcontrib><creatorcontrib>Selitsky, Sara R</creatorcontrib><creatorcontrib>Krishnan, Bhavani</creatorcontrib><creatorcontrib>Saito, Ryoichi</creatorcontrib><creatorcontrib>Iglesia, Michael D</creatorcontrib><creatorcontrib>Milowsky, Matthew I</creatorcontrib><creatorcontrib>Parker, Joel S</creatorcontrib><creatorcontrib>Kim, William Y</creatorcontrib><creatorcontrib>Vincent, Benjamin G</creatorcontrib><title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</title><title>JCI insight</title><addtitle>JCI Insight</addtitle><description>We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of
,
, and
mutations; increased frequency of
amplification; decreased rates of
,
, and
mutations; and decreased frequency of
amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low
activity, allowing unopposed
activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response.</description><subject>Antigens, Neoplasm - metabolism</subject><subject>Chemokines - immunology</subject><subject>Claudins - genetics</subject><subject>Cytokines - immunology</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>Leukocytes - immunology</subject><subject>NF-kappa B - metabolism</subject><subject>PPAR gamma - metabolism</subject><subject>Tumor Microenvironment</subject><subject>Urinary Bladder Neoplasms - classification</subject><subject>Urinary Bladder Neoplasms - genetics</subject><subject>Urinary Bladder Neoplasms - immunology</subject><issn>2379-3708</issn><issn>2379-3708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUclOwzAQtRCIVoUP4IJy5JJix7EdX5BQxSZVggOcLSceg5GzYCdF_XsCXVQOozfSvHmzPIQuCJ4TIrLrz8rNXRPd-0c_L5jE2RGaZlTIlApcHB_kE3Qe4yfGmIg8w6w4RZNMcCkzxqfoZeH1YFyT-vY7Kb02BkLSD3UbYqIDJK6uh2aExjrfB92DSXQzRtW7Ffj1rh6HrgsQI5gzdGK1j3C-xRl6u797XTymy-eHp8XtMq1yLvu0tDRnwCyWhQEJJCecSIYLzom1UGLKy3K8iUujMZQ8M4AFtVpkAqStANMZutnodkNZg6mgGdfzqguu1mGtWu3U_0rjPtR7u1IMUypJPgpcbQVC-zVA7FXtYgXe6wbaISpSUEaZkJiNVLKhVqGNMYDdjyFY_ZqhRjPU1gz1Z8bYc3m4375j93r6A-s-iu0</recordid><startdate>20160317</startdate><enddate>20160317</enddate><creator>Kardos, Jordan</creator><creator>Chai, Shengjie</creator><creator>Mose, Lisle E</creator><creator>Selitsky, Sara R</creator><creator>Krishnan, Bhavani</creator><creator>Saito, Ryoichi</creator><creator>Iglesia, Michael D</creator><creator>Milowsky, Matthew I</creator><creator>Parker, Joel S</creator><creator>Kim, William Y</creator><creator>Vincent, Benjamin G</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160317</creationdate><title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</title><author>Kardos, Jordan ; Chai, Shengjie ; Mose, Lisle E ; Selitsky, Sara R ; Krishnan, Bhavani ; Saito, Ryoichi ; Iglesia, Michael D ; Milowsky, Matthew I ; Parker, Joel S ; Kim, William Y ; Vincent, Benjamin G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antigens, Neoplasm - metabolism</topic><topic>Chemokines - immunology</topic><topic>Claudins - genetics</topic><topic>Cytokines - immunology</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>Leukocytes - immunology</topic><topic>NF-kappa B - metabolism</topic><topic>PPAR gamma - metabolism</topic><topic>Tumor Microenvironment</topic><topic>Urinary Bladder Neoplasms - classification</topic><topic>Urinary Bladder Neoplasms - genetics</topic><topic>Urinary Bladder Neoplasms - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kardos, Jordan</creatorcontrib><creatorcontrib>Chai, Shengjie</creatorcontrib><creatorcontrib>Mose, Lisle E</creatorcontrib><creatorcontrib>Selitsky, Sara R</creatorcontrib><creatorcontrib>Krishnan, Bhavani</creatorcontrib><creatorcontrib>Saito, Ryoichi</creatorcontrib><creatorcontrib>Iglesia, Michael D</creatorcontrib><creatorcontrib>Milowsky, Matthew I</creatorcontrib><creatorcontrib>Parker, Joel S</creatorcontrib><creatorcontrib>Kim, William Y</creatorcontrib><creatorcontrib>Vincent, Benjamin G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JCI insight</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kardos, Jordan</au><au>Chai, Shengjie</au><au>Mose, Lisle E</au><au>Selitsky, Sara R</au><au>Krishnan, Bhavani</au><au>Saito, Ryoichi</au><au>Iglesia, Michael D</au><au>Milowsky, Matthew I</au><au>Parker, Joel S</au><au>Kim, William Y</au><au>Vincent, Benjamin G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</atitle><jtitle>JCI insight</jtitle><addtitle>JCI Insight</addtitle><date>2016-03-17</date><risdate>2016</risdate><volume>1</volume><issue>3</issue><spage>e85902</spage><epage>e85902</epage><pages>e85902-e85902</pages><issn>2379-3708</issn><eissn>2379-3708</eissn><abstract>We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of
,
, and
mutations; increased frequency of
amplification; decreased rates of
,
, and
mutations; and decreased frequency of
amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low
activity, allowing unopposed
activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>27699256</pmid><doi>10.1172/jci.insight.85902</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2379-3708 |
ispartof | JCI insight, 2016-03, Vol.1 (3), p.e85902-e85902 |
issn | 2379-3708 2379-3708 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5033914 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Antigens, Neoplasm - metabolism Chemokines - immunology Claudins - genetics Cytokines - immunology Humans Immune Tolerance Leukocytes - immunology NF-kappa B - metabolism PPAR gamma - metabolism Tumor Microenvironment Urinary Bladder Neoplasms - classification Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - immunology |
title | Claudin-low bladder tumors are immune infiltrated and actively immune suppressed |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A27%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Claudin-low%20bladder%20tumors%20are%20immune%20infiltrated%20and%20actively%20immune%20suppressed&rft.jtitle=JCI%20insight&rft.au=Kardos,%20Jordan&rft.date=2016-03-17&rft.volume=1&rft.issue=3&rft.spage=e85902&rft.epage=e85902&rft.pages=e85902-e85902&rft.issn=2379-3708&rft.eissn=2379-3708&rft_id=info:doi/10.1172/jci.insight.85902&rft_dat=%3Cproquest_pubme%3E1835357905%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835357905&rft_id=info:pmid/27699256&rfr_iscdi=true |